Education
About Us
Working with TipRanks
Follow Us
MetaVia (MTVA)
NASDAQ:MTVA
MTVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.29 - $5.30
Previous CloseN/A
Volume36.62K
Average Volume (3M)25.94K
Market Cap
$12.64M
Enterprise Value$1.65M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)100.00K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 21, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.32
Shares Outstanding8,654,869
10 Day Avg. Volume30,166
30 Day Avg. Volume25,937
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside516.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
MetaVia News
PremiumCompany Announcements
MetaVia Inc. Reports Progress in Cardiometabolic Drug Development
PremiumCompany Announcements
MetaVia Advances Therapeutics with Promising Trial Updates
PremiumCompany Announcements
MetaVia Reports Positive Phase 2a Clinical Trial Results---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressPositive data from the DA-1726 study should be a catalyst for shares and position the company to move into the Part 3 proof of concept portion of the P1 in obesity patients.
Metabolic EffectsDA-1241 also significantly lowered A1C which Rezdeffra cannot do, pointing to the more broad metabolic changing potential of DA-1241.
Bears Say
Capital NeedsThe company will likely need to raise capital soon which we factor in.
Stock PressureShares of MTVA are under pressure, down ~20%, stemming from a combination of misunderstanding of the data itself and activity in the obesity/metabolic space from Merck which is also pressuring Viking shares.
---
Ownership Overview
63.84% Insiders
1.10% Mutual Funds
8.46% Other Institutional Investors
25.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $1.29 and its highest was $5.30 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $12.64M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is May 21, 2025 which is in 44 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on Mar 20, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of -$0.678 by $0.838.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.3.
How many shares outstanding does MetaVia have?
MetaVia has 8,654,869 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of $0.16 in its last earnings report, beating expectations of -$0.678. Following the earnings report the stock price went down -2.516%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
---
Company Description
MetaVia
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
---
MTVA Stock 12 Month Forecast
Average Price Target
$9.00
▲(516.44% Upside)
Technical Analysis
Best Analysts Covering MTVA
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-43.15%
reiterated a buy rating 15 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -43.15% per trade.
---